

BÖLÜM

19

Diferansiyel Tiroid Kanseri Takibinde Ultrasonografi ve Konvansiyonel Görüntülemeler

Doç. Dr. Ahmet DİRİKOÇ
Doç. Dr. Hüsnüye BAŞER

Özet

Diferansiyel tiroid karsinomu (DTK)'nun klinik ve epidemiyolojik seyri son yıllarda hızla değişmektedir. Güncel pratik seçilmiş hastalarda total tiroidektomi yerine lobektomi ve radyoaktif iyodun selektif kullanım gibi daha konservatif yaklaşılara doğru yönelmiştir. Bu değişim tanışal görüntüleme alanındaki hızlı teknolojik gelişmeye paralel ve kısmen de onun desteğiyledir. Servikal ultrasonografi (US), DTK'lı hastaların postoperatif takibinde kullanılabilecek basit, invaziv olmayan ve oldukça duyarlı bir yöntemdir. Servikal US'nin, lokal ya da nodal rekürrensi belirlemedeki faydası uluslararası rehberlerde de belirtildi. Servikal US'nin tam olarak hastalığı tarif edemediği rekürren nodüler hastalıkda, potansiyel aerodigestif trakt invazyonu olan muhtemel invaziv rekürren hastalık değerlendirilmesinde, US'nin olası boyun nodal hastalığının görüntülenmesinde yetersiz olduğu düşünülen vakalarda, yüksek serum tiroglobulin (Tg) düzeyi veya artan Tg antikoru olan yüksek riskli DTK'lı hastalarda ise bilgisayarlı tomografi (BT) veya manyetik rezonans görüntüleme (MRG) ile yapılan kesitsel incelemeler önemlidir. Bu bölümde DTK'lı hastaların takibinde US, BT ve MRG tekniklerinin kullanımı, benign ve malign servikal lenf nodlarının sonografik özellikleri konusu özetlenmiştir.

Kaynaklar

1. Mazzaferrri EL, Jhian SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *American Journal of Medicine* 1994;97(5): 418–28.
2. Mazzaferrri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. *J Clin Endocrinol Metab* 2001;86(4): 1447–63.
3. Davies L, Ouellette M, Hunter M, Welch HG. The increasing incidence of small thyroid cancers: where are the cases coming from? *Laryngoscope* 2010; 120(12): 2446–51.
4. Sosa JA, Hanna JW, Robinson KA, Lanman RB. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. *Surgery* 2013; 154(6): 1420–6.
5. Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. *World J Surg* 2010;34(1): 28–35.
6. Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. *World J Surg* 2010;34(6): 1222–31.
7. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016;26(1): 1–133.
8. Schlumberger MJ. Papillary and follicular thyroid carcinoma. *N Engl J Med* 1998;338(5):297–306.
9. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in ultrasound consensus conference statement. *Radiology* 2005; 237(3):794–800.
10. Frasoldati A, Pesenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. *Cancer* 2003;97(1):90–6.
11. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. *Eur J Endocrinol* 2004; 150(2):105–12.
12. Durante C, Filetti S. Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography. *J Clin Endocrinol Metab* 2011;96(10): 3059–61.
13. Kouvaraki MA, Shapiro SE, Fornage BD, et al. 2003 Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery* 134(6):946–54.
14. Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. *J Clin Endocrinol Metab* 2006;91(1):60–3.
15. Leenhardt L, Erdogan MF, Hegele L, et al. 2013 European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. *Eur Thyroid J* 2013;2(3): 147–59.
16. Frates MC. Ultrasound in recurrent thyroid disease. *Otolaryngol Clin North Am* 2008; 41(6):1107–16.
17. Lee JH, Lee HK, Lee DH, et al. Ultrasonographic findings of a newly detected nodule on the thyroid bed in postoperative patients for thyroid carcinoma: correlation with the results of ultrasonography-guided fine-needle aspiration biopsy. *Clin Imaging* 2007; 31(2):109–13.
18. Ko MS, Lee JH, Shong YK, et al. Normal and abnormal sonographic findings at the thyroidectomy sites in postoperative patients with thyroid malignancy. *AJR Am J Roentgenol* 2010;194(6):1596–1609.
19. Hahn SY, Shin JH, Han BK, et al. Predictive factors related to the recurrence at US-guided fine needle aspiration in postoperative patients with differentiated thyroid cancer. *Clin Endocrinol (Oxf)* 2012;74(2):270–5.
20. Kuna SK, Bracic I, Tesic V, et al. Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. *J Ultrasound Med* 2006;25(12):1531–40.
21. Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. *J Clin Endocrinol Metab* 2007;92(9): 3590–4.
22. Park JS, Son KR, Na DG, et al. Performance of preoperative sonographic staging of papillary thyroid carcinoma based on the sixth edition of the AJCC/UICC TNM classification system. *AJR Am J Roentgenol* 2009;192(1): 66–72.
23. Sohn YM, Kwak JY, Kim EK, et al. Diagnostic approach for evaluation of lymph node metastasis from thyroid cancer using ultrasound and fine-needle aspiration biopsy. *AJR Am J Roentgenol* 2010;194(1): 38–43.
24. Steinkamp HJ, Cornehl M, Hosten N, et al. Cervical lymphadenopathy: ratio of long- to short-axis diameter as a predictor of malignancy. *Br J Radiol* 1995;68(807): 266–70.
25. do Rosario PW, Fagundes TA, Maia FF, et al. Sonography in the diagnosis of cervical recurrence in patients with differentiated thyroid carcinoma. *J Ultrasound Med* 2004;23(7): 915–20.
26. Machens A, Holzhausen HJ, Dralle H. Skip metastases in thyroid cancer leaping the central lymph node compartment. *Arch Surg* 2004;139(1): 43–5.
27. Lyschik A, Moses R, Barnes SL, et al. Quantitative analysis of tumor vascularity in benign and malignant solid thyroid nodules. *J Ultrasound Med* 2007;26(6): 837–46.
28. Alam F, Naito K, Horiguchi J, et al. Accuracy of sonographic elastography in the differential diagnosis of enlarged cervical lymph nodes: comparison with conventional B-mode sonography. *AJR Am J Roentgenol* 2008;191(2): 604–10.
29. Ahuja A and Ying M. Sonography of neck lymph nodes. Part II: abnormal lymph nodes. *Clin Radiol* 2003;58(5): 359–66.
30. Machado MR, Tavares MR, Buchpiguel CA, Chammas MC. Ultrasonographic Evaluation of Cervical Lymph Nodes in Thyroid Cancer. *Otolaryngol Head Neck*

- Surg 2017;156(2): 263–71.
31. Kobayashi K, Hirokawa M, Yabuta T, et al. Tumor thrombus of thyroid malignancies in veins: importance of detection by ultrasonography. Thyroid 2011;21(5): 527–31.
 32. Marcy PY, Thariat J, Bozec A, et al. Venous obstruction of thyroid malignancy origin: the Antoine Lacassagne institute experience. World J Surg Oncol 2009;7:40.
 33. Kim DW. Long-term follow-up ultrasonography after lobectomy in papillary thyroid microcarcinoma patients: a single-center study. Endocr Res. 2016;41(3): 213–7.
 34. Durante C, Montesano T, Torloni M, , et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98(2): 636–42.
 35. Park HK, Kim DW, Ha TK, et al. Utility of routine ultrasonography follow-up after total thyroidectomy in patients with papillarythyroid carcinoma: a single-center study. BMC Med Imaging 2018;18(1):12
 36. Solorzano CC, Carneiro DM, Ramirez M, et al. Surgeon-performed ultrasound in the management of thyroid malignancy. Am Surg 2004;70(7):576–580.
 37. Nascimento C, Borget I, Al Ghuzlan A, et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 2011;18(2):R29–R40.
 38. Leenhardt L, Borson-Chazot F, Calzada M, et al. Good practice guide for cervical ultrasound scan and echo-guided techniques in treating differentiated thyroid cancer of vesicular origin. Ann Endocrinol (Paris) 2011;72(3): 173– 97.
 39. Cooper DS, Doherty GM, Hagen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11): 1167–214.
 40. Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006;141(5): 489–94.
 41. Castagna MG, Maino F, Cipri C, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011;165(3): 441–6.
 42. Vaisman F, Shaha A, Fish S, Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 2011;75(1): 112–9.
 43. Kloos RT. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93(5): 1519–25.
 44. Frasoldati A, Pesenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003;97(1): 90–6.
 45. Schlumberger M, Pacini F, Wiersinga WM, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004;151(5): 539–48.
 46. Shin JH, Baek HJ, Chung J, et al. Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol 2016; 17: 370–95.
 47. Wu LM, Gu HY, Qu XH, et al. The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: a meta-analysis. Eur J Radiol 2012;81: 1798–805.
 48. Lim JH, Kim DW, Park JY, et al. Ultrasonography, Cytology, and Thyroglobulin Measurement Results of Cervical Nodal Metastasis in Patients With Unclear Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) 2019 ;10:395.
 49. Spencer C, Fatemi S, Singer P, et al. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010;20(6): 587–95.
 50. Bachelot A, Cailleux AF, Klain M, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12(8): 707–11.
 51. Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. Journal of Clinical Endocrinology and Metabolism 2014;99(6): 1970–82.
 52. Jeon MJ, Kim WG, Jang EK, et al. Thyroglobulin level in fine-needle aspirates for preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: two different cutoff values according to serum thyroglobulin level. Thyroid 2015;25(4): 410–6.
 53. Lang BH, Lee GC, Ng CP, et al. Evaluating the morbidity and efficacy of reoperative surgery in the central compartment for persistent/recurrent papillary thyroid carcinoma. World Journal of Surgery 2013;37(12): 2853–9.
 54. Onkendi EO, McKenzie TJ, Richards ML, et al. Reoperative experience with papillary thyroid cancer. World Journal of Surgery 2014;38(3): 645–52.
 55. Snozek CL, Chambers EP, Reading CC, et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 2007;92(11): 4278–81.
 56. Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006; 91(4): 1364–9.
 57. Yoon DY, Hwang HS, Chang SK, et al. CT, MR, US,18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol 2009;19(3): 634–42.
 58. Spate VL, Morris JS, Nichols TA, et al. Longitudinal study of iodine in toenails following IV administration of an iodine-containing contrast

- agent. *Journal of Radioanalytical and Nuclear Chemistry* 1998;236: 71–7.
59. Sohn SY, Choi JH, Kim NK, et al. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. *Thyroid* 2014;24: 872–7.
60. Ho JD, Tsang JF, Scoggan KA, et al. Urinary iodine clearance following iodinated contrast administration: a comparison of euthyroid and postthyroidectomy subjects. *J Thyroid Res* 2014;2014:580569.
61. Padovani RP, Kasamatsu TS, Nakabashi CC, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in postthyroidectomy patients requiring radioiodine therapy. *Thyroid* 2012;22(9): 926–30.
62. Jeong HS, Baek CH, Son YI, et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. *Clin Endocrinol (Oxf)* 2006;65(3): 402–7.
63. Lesnik D, Cunnane ME, Zurakowski D, et al. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. *Head Neck* 2014;36(2):191–202.
64. Na DK, Choi YJ, Choi SH, et al. Evaluation of cervical lymph node metastasis in thyroid cancer patients using real-time CT-navigated ultrasonography: preliminary study. *Ultrasonography* 2015;34(1):39–44.
65. Wei Q, Wu D, Luo H, et al. Features of lymph node metastasis of papillary thyroid carcinoma in ultrasonography and CT and the significance of their combination in the diagnosis and prognosis of lymph node metastasis. *J BUON* 2018;23(4):1041–8.
66. Suh CH, Baek JH, Choi YJ, Lee JH. Performance of CT in the Pre-operative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis. *AJNR Am J Neuroradiol* 2017;38(1):154–61.
67. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. *JAMA* 2007; 298(3): 317–23.
68. Wang JC, Takashima S, Takayama F, et al. Tracheal invasion by thyroid carcinoma: prediction using MR imaging. *AJR. American Journal of Roentgenology* 2001;177(4): 929–36.
69. Wang J, Takashima S, Matsushita T, et al. Esophageal invasion by thyroid carcinomas: prediction using magnetic resonance imaging. *Journal of Computer Assisted Tomography* 2003; 27(1):18–25.
70. Gross ND, Weissman JL, Talbot JM, et al. MRI detection of cervical metastasis from differentiated thyroid carcinoma. *Laryngoscope* 2001;111(11 Pt 1): 1905–9.
71. Touber ME, Cyna-Gorse F, Zagdanski AM, et al. Cervicomediastinal magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits. *Thyroid* 1999;9(6):591–7.
72. Wang H, Liu K, ren J, et al. Magnetic Resonance Imaging Characteristics of Papillary Thyroid Carcinoma for the Prediction of Cervical Central Compartment Lymph Node Metastasis. *J Comput Asist Tomogr* 2019 May 31. doi: 10.1097/RCT.0000000000000883
73. Shindo ML, Caruana S, Kandil E, et al. Management of invasive well-differentiated thyroid cancer an American Head and Neck Society consensus statement. *Head Neck* 2014;36(10): 1379–90.
74. Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma. *Endocrine-Related Cancer* 2008;15(1): 37–49.
75. Schmidt GP, Schoenberg SO, Schmidt R, et al. Screening for bone metastases: wholebody MRI using a 32-channel system versus dual-modality PET-CT. *European Radiology* 2007;17(4): 939–49.
76. Sakurai Y, Kawai H, Iwano S, et al. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. *Journal of Medical Imaging and Radiation Oncology* 2013;57(3): 297–305.
77. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. *Journal of Neuro-Oncology* 1999;44(3):275–81.
78. Salvatori M, Perotti G, Rufini V, et al. Solitary liver metastasis from Hürthle cell thyroid cancer: a case report and review of the literature. *Journal of Endocrinological Investigation* 2004; 27(1): 52–6.
79. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. *Journal of Clinical Endocrinology and Metabolism* 2007;92(11): 4185–90.
80. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. *Journal of Clinical Oncology* 2005;23(1): 70–8.